Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin Choy

Showing results (121-130 of 180) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated LiposarcomaMatthew Ingham, Shing Lee, Brian A Van Tine, et al.
Nature Communications|September 1, 2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcomaJoonil Jung, Joon Sang Lee, Mark A Dickson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 13, 2019
Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNSTRuoyu Miao, Haotong Wang, Alex Jacobson, et al.
BMC Cancer|November 7, 2014
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapyEdwin Choy, James E Butrynski, David C Harmon, et al.
Cancer|December 25, 2014
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcomaEdwin Choy, Yael Flamand, Sriram Balasubramanian, et al.
International Journal of Radiation Oncology, Biology, Physics|December 30, 2014
Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculatureHae-June Lee, Changhwan Yoon, Do Joong Park, et al.
Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.
Annals of Surgical Oncology|March 5, 2009
Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomasUgwuji N Maduekwe, Francis J Hornicek, Dempsey S Springfield, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 16, 2022
Definitive high-dose, proton-based radiation for unresected mobile spine and sacral chordomasWalter Banfield, Myrsini Ioakeim-Ioannidou, Saveli Goldberg, et al.
Advances in Radiation Oncology|July 26, 2017
Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomasThomas F DeLaney, Yen-Lin Chen, Elizabeth H Baldini, et al.
Pageof 18

Showing results (121-130 of 180) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated LiposarcomaMatthew Ingham, Shing Lee, Brian A Van Tine, et al.
Nature Communications|September 1, 2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcomaJoonil Jung, Joon Sang Lee, Mark A Dickson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 13, 2019
Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNSTRuoyu Miao, Haotong Wang, Alex Jacobson, et al.
BMC Cancer|November 7, 2014
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapyEdwin Choy, James E Butrynski, David C Harmon, et al.
Cancer|December 25, 2014
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcomaEdwin Choy, Yael Flamand, Sriram Balasubramanian, et al.
International Journal of Radiation Oncology, Biology, Physics|December 30, 2014
Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculatureHae-June Lee, Changhwan Yoon, Do Joong Park, et al.
Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.
Annals of Surgical Oncology|March 5, 2009
Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomasUgwuji N Maduekwe, Francis J Hornicek, Dempsey S Springfield, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 16, 2022
Definitive high-dose, proton-based radiation for unresected mobile spine and sacral chordomasWalter Banfield, Myrsini Ioakeim-Ioannidou, Saveli Goldberg, et al.
Advances in Radiation Oncology|July 26, 2017
Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomasThomas F DeLaney, Yen-Lin Chen, Elizabeth H Baldini, et al.
Pageof 18